40834-86-4

Basic information

• Product Name: 5-(benzoyloxy)-3,3a,4,5,6,6a-hexahydro-4-(3-oxo-1-octenyl)-2H-cyclopenta(b)furan-2-one
• Synonyms: 5-(benzoyloxy)-3,3a,4,5,6,6a-hexahydro-4-(3-oxo-1-octenyl)-2H-cyclopenta(b)furan-2-one;DN-BK;(3AR,4R,5R,6aS)-2-Oxo-4-((E)-3-oxooct-1-en-1-yl)-hexahydro-2H-cyclopenta[b]furan-5-yl benzoate;2H-Cyclopenta[b]furan-2-one, 5-(benzoyloxy)hexahydro-4-[(1E)-3-oxo-1-octen-1-yl]-, (3aR,4R,5R,6aS)-
• CAS NO: 40834-86-4
• Molecular Formula: C₂₂H₂₆O₅
• Molecular Weight: 370.44
• Mol File: 40834-86-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 546.8 °C at 760 mmHg
• Flash Point: 238.3 °C
• Appearance: /
• Density: 1.18 g/cm³
• Refractive Index: 1.554
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-(benzoyloxy)-3,3a,4,5,6,6a-hexahydro-4-(3-oxo-1-octenyl)-2H-cyclopenta(b)furan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(benzoyloxy)-3,3a,4,5,6,6a-hexahydro-4-(3-oxo-1-octenyl)-2H-cyclopenta(b)furan-2-one(40834-86-4)
• EPA Substance Registry System: 5-(benzoyloxy)-3,3a,4,5,6,6a-hexahydro-4-(3-oxo-1-octenyl)-2H-cyclopenta(b)furan-2-one(40834-86-4)

Safety Data

• Hazardous Substances Data: 40834-86-4(Hazardous Substances Data)

Usage

General Description

5-(benzoyloxy)-3,3a,4,5,6,6a-hexahydro-4-(3-oxo-1-octenyl)-2H-cyclopenta(b)furan-2-one, also known as 3-Oxo-1-octenyl hydrobenzoate, is a synthetic organic compound with a complex molecular structure. It is a derivative of furan with a benzoyloxy group and a 3-oxo-1-octenyl side chain. This chemical is commonly used in the synthesis of pharmaceuticals and as a flavoring agent in the food industry. It has a wide range of potential applications in various industries due to its unique chemical properties and structure.

InChI:InChI=1/C22H26O5/c1-2-3-5-10-16(23)11-12-17-18-13-21(24)26-20(18)14-19(17)27-22(25)15-8-6-4-7-9-15/h4,6-9,11-12,17-20H,2-3,5,10,13-14H2,1H3

Upstream product

• 33803-58-6 1-(triphenylphosphoranylidene)-2-heptanone 
• 39746-01-5 (1S,5R,6R,7R)-6-formyl-7-benzoyloxy-2-oxabicyclo[3.3.0]octan-3-one 
• 36969-89-8 dimethyl 2-oxoheptylphosphonate 
• 61728-15-2 2-oxohexylphosphonic acid dimethyl ester 

Downstream Products

• 51705-58-9 [3aR,4R(1E,3R),5R,6aS]-5-benzoyloxy-4-(3-hydroxyocten-1-yl)-hexahydro-2H-cyclopenta[b]furan-2-one 
• 40834-88-6 [3aR,4R(1E,3S),5R,6aS]-5-benzoyloxy-4-(3-hydroxyocten-1-yl)-hexahydro-2H-cyclopenta[b]furan-2-one 
• 1056034-74-2 (3aR,4R,5R,6aS)-4-((E)-3-hydroxy-3-methyloct-1-enyl)-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl benzoate 
• 1151944-14-7 (3aR,4R,5R,6aS)-4-((E)-3,3-difluorooct-1-enyl)-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl benzoate 
• 587869-87-2 (5Z)-7-{(1RS,2SR,5RS)-2-[(1E,3SR)-3-(tert-butyldimethylsilanyloxy)oct-1-enyl]-5-(2-nitrophenylselanyl)cyclopent-3-enyl}hept-5-enoic acid methyl ester 
• 587869-81-6 (3aR,4R,5R,6aS)-benzoic acid 4-[(1E,3S)-3-(tert-butyl-dimethylsilanyloxy)-oct-1-enyl]-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 
• 60203-57-8 prostaglandin J₂ 
• 733037-18-8 [3aR,4R(3S),5R,6aS]-5-benzoyloxy-4-(3-fluorooctyl)-hexahydro-2H-cyclopenta[b]furan-2-one 
• 69224-05-1 [3aR,4R(3R),5R,6aS]-5-benzoyloxy-4-(3-hydroxyoctyl)-hexahydro-2H-cyclopenta[b]furan-2-one 
• 851542-03-5 Benzoic acid (3aR,4R,5R,6aS)-4-[(E)-(R)-3-(tert-butyl-dimethyl-silanyloxy)-oct-1-enyl]-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 
• 38873-82-4 (15R)-PGE2 
• 1010074-85-7 (3aR,4R,5R,6aS)-benzoic acid 4-[(1E)-3-hydroxy-oct-1-enyl]-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 

Relevant articles and documents

15-ketone preparation method

The present invention relates to a drug intermediate 15-ketone preparation method in chemical field. The preparation method comprises the following steps: (1) (-)-Corey lactone benzoate, an oxidizing agent and a catalyst are added into a first organic solvent for oxidation to obtain a reaction solution A; (2) after a dilute acid is dropwise added into the reaction solution A obtained in the step (1), the solution is stirred and filtered, the filtrate is extracted directly with the first organic solvent, an organic phase is washed with water, dehydrated with a desiccant and filtered to obtain a (-)-Corey lactone benzoate aldehyde solution; (3) Wittig reagent is added into the (-)-Corey lactone benzoate aldehyde solution obtained in the step (2) for Wittig reaction to obtain a reaction solution B, the reaction solution B is concentrated, a second organic solvent is added, and after cooling and crystallization, a crystallization liquid is obtained; and (4) the crystallization liquid obtained in the step (3) is filtered, the filter cake is washed with a third organic solvent, the filter cake is dissolved by the first organic solvent for impurity removal, and after filteration and concentration, an oil matter is obtained. The drug intermediate 15-ketone preparation method has the advantages of good product quality and the like.

Enantio- and stereospecific syntheses of 15(R)-Me-PGD2, a potent and selective DP2-receptor agonist

(Chemical Equation Presented) The first total synthesis of 15(R)-Me-PGD2 3 is reported. The synthesis is based on the enantioselective and stereospecific syntheses of synthon 17 and its attachment to the five-membered ring by a olefin cross metathesis reaction. This approach permits the introduction of a side chain with a predetermined stereogenic center into the prostanoid ring, resulting in the synthesis of 15R-methyl prostaglandin D2 and allows rapid access to other prostanoids.

Synthesis of 15R-PGD2: A potential DP2 receptor agonist

The first total synthesis of 15R-PGD2 3 was accomplished. The approach used in this report is also an efficient method to produce 15R-PGE 2. 15R-PGD2, a potential DP2 receptor agonist, could be an important novel tool for defining the role of this receptor in inflammatory diseases.